UROGEN PHARMA LTD
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 201
- Market Cap
- -
- Website
- http://www.urogen.com
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
- Conditions
- Upper Urinary Tract Urothelial CarcinomaUrothelial Carcinoma
- Interventions
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06774131
- Locations
- 🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
A Phase 3 Single-arm Study of UGN-103 for the Treatment of LG IR NMIBC.
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Urogen Pharma Ltd.
- Target Recruit Count
- 57
- Registration Number
- 2023-507261-25-00
- Locations
- 🇧🇬
University Multiprofessional Hospital For Active Treatment Plovdiv AD, Plovdiv, Bulgaria
🇧🇬Multiprofile Hospital For Active Treatment Dr. Tota Venkova AD, Gabrovo, Bulgaria
🇧🇬University Multiprofile Hospital For Active Treatment And Emergency Medicine N I Pirogov, Sofiya, Bulgaria
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- Conditions
- Urothelial CarcinomaUrothelial Carcinoma Ureter RecurrentUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma RecurrentUrothelial Carcinoma UreterUrothelial Cancer of Renal PelvisTransitional Cell Carcinoma of Renal PelvisCarcinoma, Transitional Cell
- Interventions
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT05874921
- Locations
- 🇺🇸
Providence St. Johns Health Center, Santa Monica, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Mount Sinai Medical Center of Florida, Inc., Miami, Florida, United States
Named Patient Program for Mitomycin for Pyelocalyceal Solution
- Conditions
- Urothelial Cancer of Renal PelvisUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma UreterUrothelial Carcinoma Ureter RecurrentUrothelial CarcinomaUrothelial Carcinoma Recurrent
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- UroGen Pharma Ltd.
- Registration Number
- NCT05494411
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2025-05-26
- Lead Sponsor
- Urogen Pharma Ltd.
- Target Recruit Count
- 48
- Registration Number
- 2023-508404-37-00
- Locations
- 🇮🇹
IRCCS Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
🇮🇹Ospedale San Raffaele S.r.l., Milan, Italy
🇪🇸Hospital Universitario Hm Sanchinarro, Madrid, Spain
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- Conditions
- Bladder CancerUrothelial Carcinoma BladderUrothelial Carcinoma
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05243550
- Locations
- 🇺🇸
Arizona Urology Specialists, Tucson, Arizona, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸Genesis Research, San Diego, California, United States
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)
- Conditions
- Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05136898
- Locations
- 🇺🇸
Urology Centers of Alabama (UCA), Homewood, Alabama, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸Medication Management, Greensboro, North Carolina, United States
A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- Conditions
- Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
- Interventions
- Procedure: TURBT
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 282
- Registration Number
- NCT04688931
- Locations
- 🇺🇸
Arizona Institute of Urology, PLLC, Tucson, Arizona, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸Urology Group of Southern California, Los Angeles, California, United States
Efficacy and Safety of UGN-101 in Recurrent Patients
- Conditions
- CarcinomaTransitional Cell CarcinomaTransitional Cell Cancer of the Renal Pelvis and Ureter
- Interventions
- Drug: UGN-101 instillations
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- UroGen Pharma Ltd.
- Registration Number
- NCT04006691
- Locations
- 🇺🇸
UCLA - University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸John Hopkins University, Baltimore, Maryland, United States
A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
- Conditions
- Bladder CancerUrothelial Carcinoma BladderUrothelial Carcinoma
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT03558503
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Phoenix, Arizona, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸Loma Linda University, Loma Linda, California, United States